diphenhydramine
Trade name: benadryl
Approved
Mar 4, 1946
Diphenhydramine, sold under the brand name Benadryl among others, is an antihistamine and sedative. Although generally considered sedating, diphenhydramine can cause paradoxical central nervous system stimulation in some individuals, particularly at higher doses. This may manifest as agitation, anxiety, or restlessness rather than sedation. It is a first-generation H1-antihistamine and it works by blocking certain effects of histamine, which produces its antihistamine and sedative effects. Diphenhydramine is also a potent anticholinergic. It is mainly used to treat allergies, insomnia, and symptoms of the common cold. It is also less commonly used for tremors in parkinsonism, and nausea. It is taken by mouth, injected into a vein, injected into a muscle, or applied to the skin. Maximal effect is typically around two hours after a dose, and effects can last for up to seven hours. — Wikipedia
Clinical trial activity
201 trials · 158 clinical orgs · 69 marketing orgs
Earliest trial started Nov 2, 1999 (NCT00000875)
Timeline
1940s
- Mar 4, 1946
Earliest FDA Approval
- Mar 4, 1946
McNeil — NDA Secondary Org
1950s
- Jun 1, 1951
Parke-Davis — First NDA Organization
- Jun 1, 1951
Parke-Davis — NDA Organization
- Apr 28, 1954
Forest Laboratories — Marketing Organization
- Apr 28, 1954
Forest Laboratories — NDA Secondary Org
1970s
- May 31, 1972
Alta Pharma — Marketing Organization
- Aug 7, 1972
American Home Products — Marketing Organization
- Aug 24, 1972
Barr Laboratories — Marketing Organization
- Aug 24, 1972
Heritage Pharma — Marketing Organization
- Sep 27, 1972
Watson Pharmaceuticals — Marketing Organization
- Nov 3, 1972
Fosun — Marketing Organization
- Nov 27, 1972
West-Ward Pharmaceutical — Marketing Organization
- Dec 20, 1972
Roxane Laboratories — Marketing Organization
- Jan 12, 1973
MK Labs — Marketing Organization
- Aug 13, 1973
Whiteworth Towne Paulsen — Marketing Organization
- Oct 12, 1973
Eurohlth Intl Sarl — Marketing Organization
- Oct 12, 1973
Nexgen Pharma, Inc — Marketing Organization
- Oct 25, 1973
Hikma — Marketing Organization
- Nov 14, 1973
Impax Laboratories — Marketing Organization
- Jan 18, 1974
Bausch Health Companies — Marketing Organization
- Jan 29, 1974
Dr. Reddy's Laboratories — Marketing Organization
- Feb 13, 1974
Lannett Company, Inc. — Marketing Organization
- Dec 19, 1974
Mutual Pharmaceutical — Marketing Organization
- Mar 15, 1976
International Medication — Marketing Organization
- Sep 22, 1977
Lumara Health — Marketing Organization
- Jan 25, 1979
Belmar Pharmacy — Marketing Organization
- Feb 8, 1979
Newtron Pharmaceuticals — Marketing Organization
- Feb 26, 1979
Upsher-Smith Laboratories — Marketing Organization
- Oct 30, 1979
Teva — Marketing Organization
1980s
- Mar 31, 1981
Lyphomed, Inc. — Marketing Organization
- Dec 7, 1981
Vanguard — Marketing Organization
- Jan 25, 1982
Puracap Pharmaceutical — Marketing Organization
- Feb 10, 1982
Pharmaceutical Associates — Marketing Organization
- Mar 2, 1982
Lederle — Marketing Organization
- Mar 2, 1982
American Cyanamid — Marketing Organization
- Jan 27, 1983
LNK International — Marketing Organization
- Oct 3, 1983
Halsey — Marketing Organization
- Oct 12, 1984
Wockhardt — Marketing Organization
- Jan 2, 1987
Sun Pharmaceuticals — Marketing Organization
1990s
- Sep 28, 1990
Akorn, Inc. — Marketing Organization
- Sep 28, 1990
Hi Tech Pharmaceuticals — Marketing Organization
- Sep 18, 1991
Morton Grove Pharmaceuticals — Marketing Organization
- Nov 20, 1998
Hospira — Marketing Organization
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2000s
2010s
- Nov 22, 2010
Bionpharma Inc — Marketing Organization
- Mar 5, 2012
Strides Pharma Science — Marketing Organization
- Mar 26, 2013
Fresenius — Marketing Organization
- Jan 17, 2014
Bayer — Marketing Organization
- Jan 17, 2014
Bayer — NDA Secondary Org
- Aug 22, 2018
Micro Labs Ltd India — Marketing Organization
- Oct 23, 2018
Amneal Pharmaceuticals — Marketing Organization
- Jan 25, 2019
Actavis — Marketing Organization
- Jan 25, 2019
P&L Development — Marketing Organization
- Feb 14, 2019
Aurobindo Pharma — Marketing Organization
- May 10, 2019
Perrigo — Marketing Organization
- Aug 22, 2019
Apotex — Marketing Organization
- Aug 22, 2019
Corepharma — Marketing Organization
2020s
- Sep 24, 2020
Granules India — Marketing Organization
Indications
Approved for
Studied for
- Abdominal Pain · Phase 1
- Acute Pain · Phase 3
- Alcohol-Induced Disorders · Phase 1
- Alcoholism · Phase 2
- Alcohol-Related Disorders · Phase 1
- Altitude Sickness · Phase 4
- Alzheimer Disease · Phase 3
- Anemia, Sickle Cell · Phase 1
- Anesthesia · Phase 4
- Anxiety Disorders · Phase 3
- Arthritis, Rheumatoid · Phase 4
- Arthroplasty · Phase 4
- Asthma · Phase 4
- Autism Spectrum Disorder · Phase 2
- Autistic Disorder · Phase 2
- Bacterial Infections · Phase 4
- Blood Protein Disorders · Phase 2
- Brain Edema · Phase 2
- Breast Neoplasms · Phase 3
- Cannabis · Phase 3
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Cesarean Section · Phase 3
- Chronic Urticaria · Phase 3
- Cocaine-Related Disorders · Phase 2
- Colonoscopy · Phase 4
- Cough · Phase 4
- Crohn Disease · Phase 1/Phase 2
- Dementia · Phase 3
- Depression · Phase 3
- Dermatitis, Atopic · Early Phase 1
- Dermatology · Phase 3
- Diabetic Neuropathies · Phase 2
- Diphenhydramine · Phase 4
- Drug Delivery Systems · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 1
- Eczema · Phase 3
- Emergency Service, Hospital · Phase 2
- Endometrial Neoplasms · Phase 3
- Esophageal Neoplasms · Phase 3
- Fabry Disease · Phase 4
- Gallbladder Diseases · Phase 1
- Gallstones · Phase 1
- Glycogen Storage Disease Type II · Phase 1
- Graft Rejection · Phase 2
- Graft vs Host Disease · Phase 2
- Hamartoma · Phase 1/Phase 2
- Headache · Phase 4
- Headache Disorders, Primary · Phase 2
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 3
- Heat Stress Disorders · Phase 4
- Hematologic Diseases · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hepatic Encephalopathy · Phase 2
- Hodgkin Disease · Phase 2
- Hyperthermia · Phase 4
- Hyperuricemia · Phase 1
- Hypnotics and Sedatives · Phase 4
- Hypotension, Orthostatic · Phase 1
- Immune System Diseases · Phase 2
- Immunoglobulin G4-Related Disease · Phase 2
- Inflammation · Phase 3
- Jaundice · Phase 1
- Kidney Diseases · Phase 3
- Kidney Failure, Chronic · Phase 2
- Kidney Neoplasms · Phase 2
- Kidney Transplantation · Phase 2
- Labor, Obstetric · Phase 2/Phase 3
- Leukemia · Phase 2
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Liver Diseases · Phase 2
- Liver Failure, Acute · Phase 2
- Liver Transplantation · Phase 1/Phase 2
- Lung Neoplasms · Phase 3
- Lupus Erythematosus, Systemic · Phase 3
- Lupus Nephritis · Phase 3
- Lymphoma · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 3
- Major Depressive Disorder · Phase 1
- Mastocytosis, Cutaneous · Phase 2
- Mastocytosis, Systemic · Phase 1
- Melanoma · Phase 1
- Mental Status and Dementia Tests · Phase 4
- Metabolism · Phase 1
- Migraine Disorders · Phase 4
- Multiple Myeloma · Phase 3
- Multiple Sclerosis · Phase 3
- Multiple Sclerosis, Chronic Progressive · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Nasal Obstruction · Phase 4
- Nausea · Phase 4
- Nefopam · Phase 3
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neoplasms by Histologic Type · Phase 2
- Neoplasms, Plasma Cell · Phase 2
- Neoplastic Cells, Circulating · Phase 2
- Otitis Media · Phase 3
- Ovarian Neoplasms · Phase 3
- Pain · Phase 3
- Pain Management · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pancreatitis · Phase 1
- Paraproteinemias · Phase 2
- Pharmacokinetics · Phase 4
- Pharmacology, Clinical · Phase 1
- Plasmacytoma · Phase 1
- Postoperative Pain · Phase 3
- Post-Traumatic Headache · Phase 3
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Prostatic Neoplasms · Phase 4
- Psychomotor Agitation · Phase 4
- Psychophysiologic Disorders · Phase 3
- Pure Autonomic Failure · Phase 1
- Purpura, Thrombocytopenic, Idiopathic · Phase 1
- Restless Legs Syndrome · Phase 2
- Rhinitis · Phase 3
- Rhinitis, Allergic · Phase 4
- Schizophrenia · Phase 3
- Signs and Symptoms · Phase 4
- Sleep · Phase 4
- Sleep Disorders, Intrinsic · Phase 4
- Sleep Initiation and Maintenance Disorders · Phase 3
- Spinal Stenosis · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Diseases · Phase 1
- Stomach Neoplasms · Phase 2
- Stomatitis · Phase 4
- Stomatitis, Aphthous · Phase 2
- Stroke · Phase 2
- Sweat Gland Diseases · Phase 4
- Sweating · Phase 4
- Urticaria · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Vomiting · Phase 2
- Vulvodynia · Phase 2
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
advil pm
with ibuprofen
aleve pm
with naproxen
ambenyl
with codeine
benylin
with pseudoephedrine
Approval history
- approvedMar 4, 1946
Chemistry & pharmacology
SMILES
CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl- Mol. weight
- 320.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- WikipediaDiphenhydramine ↗
- ChEMBLCHEMBL3707341 ↗
- ChEMBLCHEMBL3707215 ↗
- ChEMBLCHEMBL2105435 ↗
- ChEMBLCHEMBL1620 ↗
- ChEMBLCHEMBL1201245 ↗
- ChEMBLCHEMBL1201089 ↗
- ChEMBLCHEMBL1200967 ↗
- ChEMBLCHEMBL1200750 ↗
- WikipediaSominex ↗
- WikipediaSm-1 ↗
- WikipediaBromazine ↗
- NCATST032BI7727 ↗
- ChEMBLCHEMBL657 ↗
- NCATS8GTS82S83M ↗
Also known as
- 2-(benzhydryloxy)-n,n-dimethylethylamine
- 2-(benzhydryloxy)-n,n-dimethylethylamine
- 2-diphenylmethoxy-n,n-demthylethanamine
- 2-diphenylmethoxy-n,n-demthylethanamine
- 2-(p-bromo-alpha-phenylbenzyloxy)-n,n-dimethylethylamine
- 2-(p-bromo-alpha-phenylbenzyloxy)-n,n-dimethylethylamine
- alledryl
- alledryl
- alpha-(2-dimethylaminoethoxy)diphenylmethane
- alpha-(2-dimethylaminoethoxy)diphenylmethane
- ambodryl
- ambodryl
- ambodryl
- amodryl
- amodryl
- antitussive
- antitussive
- beldin
- beldin
- belix
- belix
- benadryl
- benadryl
- benadryl
- benadryl
- benadryl
- benadryl
- benadryl
- benadryl
- benadryl preservative free
- benadryl preservative free
- benylin
- benylin
- benzhydramine
- beta-dimethylaminoethanol diphenylmethyl ether
- beta-dimethylaminoethanol diphenylmethyl ether
- beta-dimethylaminoethyl benzhydryl ether
- beta-dimethylaminoethyl benzhydryl ether
- beta-dimethylaminoethyl p-bromobenzhydryl ether
- beta-dimethylaminoethyl p-bromobenzhydryl ether
- beta-(p-bromobenzhydryloxy)ethyldimethylamine
- beta-(p-bromobenzhydryloxy)ethyldimethylamine
- bietanautine
- bromanautine
- bromazina
- bromazina
- bromazine
- bromazine
- bromazine
- bromazine
- bromazine
- bromazine
- bromazine
- bromazinum
- bromazinum
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine
- bromodiphenhydramine hcl
- bromodiphenhydramine hcl
- bromodiphenhydramine hcl
- bromodiphenhydramine hydrochloride
- bromodiphenhydramine hydrochloride
- bromodiphenhydramine hydrochloride
- bromodiphenhydramine hydrochloride
- bromodiphenhydramine hydrochloride
- caladryl
- caladryl
- coltex
- dibenil
- dibenil
- difenhidramina
- difenhidramina
- dimedrol
- dimedrol
- diphen
- diphen
- diphenhdramine
- diphenhydramien
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine
- diphenhydramine citrate
- diphenhydramine citrate
- diphenhydramine citrate
- diphenhydramine citrate
- diphenhydramine hcl
- diphenhydramine hcl
- diphenhydramine hcl
- diphenhydramine hcl
- diphenhydramine hydrochloride
- diphenhydramine hydrochloride
- diphenhydramine hydrochloride
- diphenhydramine hydrochloride
- diphenhydramine hydrochloride
- diphenhydramine hydrochloride preservative free
- diphenhydramine hydrochloride preservative free
- diphenhydramine laurylsulfate
- diphenhydramine laurylsulfate
- diphenhydramine methylbromide
- diphenhydramine methylbromide
- diphenhydramine salicylate
- diphenhydramine tannate
- diphenhydramine tannate
- diphenhydraminum
- diphenhydraminum
- dreemon
- dytuss
- etanautine
- etanautine
- etanautine
- fedril
- gppe cough expect paed
- gppe oral soln
- histergan
- hydramine
- hydramine
- medinex
- n-(2-(diphenylmethoxy)ethyl)-n,n-dimethylamine
- n-(2-(diphenylmethoxy)ethyl)-n,n-dimethylamine
- nautamine
- nightcalm
- nytol
- nytol
- nytol one-a-night
- o-benzhydryldimethylaminoethanol
- o-benzhydryldimethylaminoethanol
- paxidorm
- probedryl
- silphen
- silphen
- sleepia
- sm-1
- sominex
- sominex
- sominex
- syntedril
- syntedril
- tixylix catarrh
- vicks formula 44
- vicks formula 44
- β-dimethylaminoethyl benzhydryl ether
- β-dimethylaminoethyl benzhydryl ether
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285031 | N/A | Dec 31, 2025 | University of British Columbia |
| NCT06910241 | Phase 3 | Jul 1, 2025 | Baptist Health, Florida Atlantic University |
| NCT06702670 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2024 | University of Texas at Houston |
| NCT06704620 | Phase 3 | Nov 30, 2024 | Tianjin Medical University |
| NCT06356571 | Phase 2 | Nov 17, 2024 | Sanofi |
| NCT06819774 | Phase 3 | Apr 22, 2024 | Shandong New Time Pharmaceutical Co., LTD |
| NCT06345261 | N/A | Apr 1, 2024 | Cairo University |
| NCT06043323 | Phase 2 | Mar 31, 2024 | University of Texas at Houston |
| NCT05896228 | Phase 2 | Mar 1, 2024 | Bristol-Myers Squibb, University of Miami |
| NCT06207305 | Phase 1/Phase 2 (Phase 2) | Jan 30, 2024 | University of Texas at Houston |
| NCT06070649 | Phase 1 | Jan 17, 2024 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University |
| NCT06083571 | Phase 2 | Jan 1, 2024 | Washington University in St. Louis |
| NCT06217367 | Phase 4 | Dec 5, 2023 | Lakehead University |
| NCT06243185 | Phase 2 | Nov 17, 2023 | Chinese Academy of Medical Sciences |
| NCT06019728 | Phase 4 | Nov 10, 2023 | Sanofi |
| NCT05977998 | Phase 2 | Sep 8, 2023 | University of Texas at Houston |
| NCT06182098 | N/A | Jun 27, 2023 | Dayton Children's Hospital |
| NCT05729555 | Phase 1 | Apr 3, 2023 | Guangzhou Kangqi Medical Technology Co., LTD, Overseas Pharmaceuticals, Ltd. |
| NCT05627557 | Phase 3 | Feb 28, 2023 | Roche |
| NCT05676216 | N/A | Jan 7, 2023 | National Taiwan University |
Organizations
Research & Development (158)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 14 | 9 | 4 | 2004 |
| University of Texas at Houston | Academic/Hospital | 12 | 11 | 3 | 2001 |
| Roche | For profit | 10 | 8 | 3 | 2004 |
| National Cancer Institute (NCI) | Government | 8 | 4 | 4 | 2002 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 8 | 8 | 3 | 1999 |
| Yeshiva University | Academic/Hospital | 8 | 8 | 4 | 2007 |
| Bayer | For profit | 7 | 7 | 3 | 2008 |
| Genentech | For profit | 7 | 6 | 2 | 2005 |
| Johnson and Johnson | For profit | 6 | 6 | 3 | 2006 |
| National Institutes of Health (NIH) | Government | 5 | 0 | 2 | 2002 |
| Pfizer | For profit | 5 | 2 | 5 | 2008 |
| GlaxoSmithKline | For profit | 4 | 1 | 3 | 2004 |
| University of California, San Francisco | Academic/Hospital | 4 | 0 | 2 | 2014 |
| Ache Laboratorios Farmaceuticos S.A. | For profit | 3 | 3 | 1 | 2011 |
| Bristol-Myers Squibb | For profit | 3 | 0 | 1 | 2015 |
| Immune Tolerance Network | Academic/Hospital | 3 | 0 | 1 | 2003 |
| JDP Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2013 |
| Mayo Clinic | Academic/Hospital | 3 | 2 | 3 | 2007 |
| McNeil | For profit | 3 | 0 | 2 | 2006 |
| Northwestern University | Academic/Hospital | 3 | 2 | 2 | 2010 |
Marketing (79)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | MKTG | May 28, 2002 |
| Actavis | For profit | MKTG | Jan 25, 2019 |
| Akorn, Inc. | For profit | MKTG | Sep 28, 1990 |
| Alpharma | For profit | MKTG | — |
| Alta Pharma | For profit | MKTG | May 31, 1972 |
| American Cyanamid | For profit | MKTG | Mar 2, 1982 |
| American Home Products | For profit | MKTG | Aug 7, 1972 |
| Amneal Pharmaceuticals | For profit | MKTG | Oct 23, 2018 |
| Anabolic Pharma | Academic/Hospital | MKTG | — |
| Apotex | For profit | SYN | Aug 22, 2019 |
| Apotex | For profit | MKTG | Aug 22, 2019 |
| Aurobindo Pharma | For profit | MKTG | Feb 14, 2019 |
| Aurobindo Pharma | For profit | SYN | May 31, 2022 |
| Barr Laboratories | For profit | MKTG | Aug 24, 1972 |
| Bausch Health Companies | For profit | MKTG | Jan 18, 1974 |
| Bayer | For profit | MKTG | Jan 17, 2014 |
| Bayer | For profit | NDA2 | Jan 17, 2014 |
| Belmar Pharmacy | For profit | MKTG | Jan 25, 1979 |
| Bionpharma Inc | For profit | MKTG | Nov 22, 2010 |
| Bionpharma Inc | For profit | SYN | Nov 22, 2010 |
| Bundy | For profit | MKTG | — |
| Corepharma | For profit | MKTG | Aug 22, 2019 |
| Cumberland Pharmaceuticals | For profit | MKTG | — |
| Dow Chemical | For profit | MKTG | — |
| Dr. Reddy's Laboratories | For profit | SYN | Jul 8, 2009 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jan 29, 1974 |
| Elkins Sinn | For profit | MKTG | — |
| Eurohlth Intl Sarl | For profit | MKTG | Oct 12, 1973 |
| Fondazione Golgi Cenci | Academic/Hospital | MKTG | — |
| Forest Laboratories | For profit | MKTG | Apr 28, 1954 |
| Forest Laboratories | For profit | NDA2 | Apr 28, 1954 |
| Fosun | For profit | MKTG | Nov 3, 1972 |
| Fresenius | For profit | MKTG | Mar 26, 2013 |
| GlaxoSmithKline | For profit | NDA2 | Dec 21, 2005 |
| Granules India | For profit | SYN | Sep 24, 2020 |
| Granules India | For profit | MKTG | Sep 24, 2020 |
| Halsey | For profit | MKTG | Oct 3, 1983 |
| Heather Pharma | For profit | MKTG | — |
| Heritage Pharma | For profit | MKTG | Aug 24, 1972 |
| Hi Tech Pharmaceuticals | For profit | MKTG | Sep 28, 1990 |
| Hikma | For profit | MKTG | Oct 25, 1973 |
| Hospira | For profit | MKTG | Nov 20, 1998 |
| Impax Laboratories | For profit | MKTG | Nov 14, 1973 |
| International Medication | For profit | MKTG | Mar 15, 1976 |
| LNK International | For profit | MKTG | Jan 27, 1983 |
| Lannett Company, Inc. | For profit | MKTG | Feb 13, 1974 |
| Lederle | For profit | MKTG | Mar 2, 1982 |
| Lumara Health | For profit | MKTG | Sep 22, 1977 |
| Lyphomed, Inc. | For profit | MKTG | Mar 31, 1981 |
| MK Labs | For profit | MKTG | Jan 12, 1973 |
| McNeil | For profit | NDA2 | Mar 4, 1946 |
| McNeil | For profit | SYN | Mar 4, 1946 |
| Micro Labs Ltd India | For profit | MKTG | Aug 22, 2018 |
| Morton Grove Pharmaceuticals | For profit | MKTG | Sep 18, 1991 |
| Mutual Pharmaceutical | For profit | MKTG | Dec 19, 1974 |
| Mylan | For profit | MKTG | Jul 12, 2005 |
| Naska Pharmacal | For profit | MKTG | — |
| Newtron Pharmaceuticals | For profit | MKTG | Feb 8, 1979 |
| Nexgen Pharma, Inc | For profit | MKTG | Oct 12, 1973 |
| P&L Development | For profit | MKTG | Jan 25, 2019 |
| Parke-Davis | For profit | NDA | Jun 1, 1951 |
| Perrigo | For profit | MKTG | May 10, 2019 |
| Pfizer | For profit | MKTG | Dec 21, 2005 |
| Pharmaceutical Associates | For profit | MKTG | Feb 10, 1982 |
| Puracap Pharmaceutical | For profit | MKTG | Jan 25, 1982 |
| Roxane Laboratories | For profit | MKTG | Dec 20, 1972 |
| Strides Pharma Science | For profit | MKTG | Mar 5, 2012 |
| Sun Pharmaceuticals | For profit | MKTG | Jan 2, 1987 |
| Superpharm | For profit | MKTG | — |
| Teva | For profit | SYN | May 9, 1972 |
| Teva | For profit | MKTG | Oct 30, 1979 |
| Teva | For profit | SYN | Jan 29, 1974 |
| Upsher-Smith Laboratories | For profit | MKTG | Feb 26, 1979 |
| Vanguard | For profit | MKTG | Dec 7, 1981 |
| Warner Chilcott | For profit | MKTG | — |
| Watson Pharmaceuticals | For profit | MKTG | Sep 27, 1972 |
| West-Ward Pharmaceutical | For profit | MKTG | Nov 27, 1972 |
| Whiteworth Towne Paulsen | For profit | MKTG | Aug 13, 1973 |
| Wockhardt | For profit | MKTG | Oct 12, 1984 |